| Market Cap | 537.14M | P/E | - | EPS this Y | 38.10% | Ern Qtrly Grth | - |
| Income | -24.06M | Forward P/E | -21.25 | EPS next Y | 46.20% | 50D Avg Chg | 20.00% |
| Sales | 169.98M | PEG | - | EPS past 5Y | - | 200D Avg Chg | - |
| Dividend | N/A | Price/Book | 10.59 | EPS next 5Y | - | 52W High Chg | -50.00% |
| Recommedations | 2.20 | Quick Ratio | 1.78 | Shares Outstanding | 185.30M | 52W Low Chg | 69.00% |
| Insider Own | 3.28% | ROA | -4.71% | Shares Float | 157.30M | Beta | 1.19 |
| Inst Own | 75.92% | ROE | -47.34% | Shares Shorted/Prior | 6.63M/6.38M | Price | 2.98 |
| Gross Margin | 55.13% | Profit Margin | -14.15% | Avg. Volume | 1,314,332 | Target Price | 4.38 |
| Oper. Margin | -8.51% | Earnings Date | Oct 31 | Volume | 1,169,571 | Change | 0.17% |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
| Cantor Fitzgerald | Overweight | May 3, 24 |
| Craig-Hallum | Buy | Apr 12, 24 |
| Stephens & Co. | Equal-Weight | Mar 7, 24 |
| Cantor Fitzgerald | Overweight | Mar 6, 24 |
| BTIG | Neutral | Jan 20, 23 |
| Stifel | Buy | May 27, 20 |
| Stephens & Co. | Overweight | Apr 16, 20 |
| BTIG | Buy | Feb 26, 20 |
| BTIG | Buy | Nov 13, 19 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BJERKHOLT ERIC | Director Director | Dec 13 | Buy | 1.62 | 10,000 | 16,200 | 142,133 | 12/13/23 |
| Lucena Ann | Director Director | Aug 22 | Buy | 1.685 | 7,500 | 12,638 | 72,284 | 08/23/23 |
| BJERKHOLT ERIC | Director Director | Aug 21 | Buy | 1.7151 | 10,000 | 17,151 | 132,133 | 08/23/23 |
| Swisher Daniel N JR | Director Director | May 26 | Buy | 1.907 | 5,000 | 9,535 | 118,808 | 05/30/23 |
| SCHULZE GAIL | Director Director | May 24 | Buy | 2.0285 | 9,850 | 19,981 | 83,420 | 05/24/23 |
| BJERKHOLT ERIC | Director Director | May 23 | Buy | 2.00 | 5,000 | 10,000 | 82,133 | 05/23/23 |
| Moore Carol | SVP Reg. & Quality SVP Reg. & Quality | Mar 12 | Sell | 2.8 | 13,078 | 36,618 | 415,915 | 03/14/23 |
| Jayaraman Vivek K | Chief Operating Offi.. Chief Operating Officer | Mar 12 | Sell | 2.8 | 25,356 | 70,997 | 658,070 | 03/14/23 |
| Menard Chrystal | Chief Legal Officer Chief Legal Officer | Mar 12 | Sell | 2.8 | 15,468 | 43,310 | 349,530 | 03/14/23 |
| Greenman William Mariner | President and CEO President and CEO | Mar 12 | Sell | 2.8 | 60,480 | 169,344 | 2,658,346 | 03/14/23 |
| Green Kevin Dennis | Chief Financial Offi.. Chief Financial Officer | Mar 12 | Sell | 2.8 | 17,163 | 48,056 | 435,963 | 03/14/23 |
| CORASH LAURENCE M | Chief Scientific Off.. Chief Scientific Officer | Mar 12 | Sell | 2.8 | 15,342 | 42,958 | 2,261,501 | 03/14/23 |
| Benjamin Richard J | Chief Medical Office.. Chief Medical Officer | Mar 12 | Sell | 2.79 | 25,353 | 70,735 | 347,439 | 03/14/23 |
| SCHULZE GAIL | Director Director | Dec 28 | Option | 3.19 | 25,000 | 79,750 | 73,570 | 01/03/23 |
| Menard Chrystal | Chief Legal Officer Chief Legal Officer | Aug 15 | Sell | 5.18 | 10,000 | 51,800 | 164,871 | 08/17/22 |
| Benjamin Richard J | Chief Medical Office.. Chief Medical Officer | Aug 09 | Sell | 5.1194 | 10,000 | 51,194 | 172,665 | 08/11/22 |
| Green Kevin Dennis | Chief Financial Offi.. Chief Financial Officer | May 10 | Sell | 4.9773 | 57,335 | 285,373 | 222,999 | 05/12/22 |
| Moore Carol | SVP Reg. & Quality SVP Reg. & Quality | Mar 12 | Sell | 5.04 | 28,513 | 143,706 | 279,268 | 03/16/22 |
| Menard Chrystal | Chief Legal Officer Chief Legal Officer | Mar 12 | Sell | 5.04 | 30,307 | 152,747 | 174,871 | 03/16/22 |
| Greenman William Mariner | President and CEO President and CEO | Mar 12 | Sell | 5.04 | 165,021 | 831,706 | 1,967,192 | 03/15/22 |
| Jayaraman Vivek K | Chief Operating Offi.. Chief Operating Officer | Mar 12 | Sell | 5.04 | 41,734 | 210,339 | 369,414 | 03/15/22 |
| CORASH LAURENCE M | Chief Scientific Off.. Chief Scientific Officer | Mar 12 | Sell | 5.04 | 30,307 | 152,747 | 2,126,716 | 03/15/22 |
| Green Kevin Dennis | Chief Financial Offi.. Chief Financial Officer | Mar 12 | Sell | 5.04 | 32,102 | 161,794 | 280,334 | 03/15/22 |
| Benjamin Richard J | Chief Medical Office.. Chief Medical Officer | Mar 12 | Sell | 5.04 | 30,307 | 152,747 | 182,665 | 03/15/22 |
| Greenman William Mariner | President and CEO President and CEO | Feb 25 | Option | 3.75 | 380,000 | 1,425,000 | 1,902,281 | 03/01/22 |
| Greenman William Mariner | President and CEO President and CEO | Feb 25 | Sell | 5.71 | 308,263 | 1,760,182 | 1,594,018 | 03/01/22 |
| SCHULZE GAIL | Director Director | Nov 09 | Option | 2.86 | 25,000 | 71,500 | 53,116 | 11/09/21 |
| SCHULZE GAIL | Director Director | Nov 09 | Sell | 7.54 | 25,000 | 188,500 | 28,116 | 11/09/21 |
| Moore Carol | SVP Reg. & Quality SVP Reg. & Quality | Nov 05 | Option | 3.75 | 110,000 | 412,500 | 289,555 | 11/09/21 |
| Moore Carol | SVP Reg. & Quality SVP Reg. & Quality | Nov 05 | Sell | 7.94 | 110,000 | 873,400 | 181,276 | 11/09/21 |
| Green Kevin Dennis | Chief Financial Offi.. Chief Financial Officer | Nov 03 | Option | 3.75 | 95,000 | 356,250 | 248,740 | 11/05/21 |
| Green Kevin Dennis | Chief Financial Offi.. Chief Financial Officer | Nov 03 | Sell | 7 | 95,741 | 670,187 | 152,999 | 11/05/21 |
| Benjamin Richard J | Chief Medical Office.. Chief Medical Officer | Nov 03 | Option | 4.46 | 165,000 | 735,900 | 107,702 | 11/05/21 |
| Benjamin Richard J | Chief Medical Office.. Chief Medical Officer | Nov 03 | Sell | 7.53 | 165,000 | 1,242,450 | 76,035 | 11/05/21 |